Upcoming Earnings Release Schedules, Board Nominations, Strategic Investments and FDA Responses - Research Report on Zimmer, ResMed, Varian, Opko and EnteroMedics

NEW YORK, October 15, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Zimmer Holdings, Inc. (NYSE: ZMH), ResMed Inc. (NYSE: RMD), Varian Medical Systems Inc. (NYSE: VAR), Opko Health, Inc. (NYSE: OPK) and EnteroMedics, Inc. (NASDAQ: ETRM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Zimmer Holdings, Inc. Research Report  

On October 10, 2013, Zimmer Holdings, Inc. (Zimmer) announced that it will report its Q3 2013 sales and earnings results through a news release on Thursday October 24, 2013 at 7:00 a.m. E.T. The Company informed that it will also host a conference call on the same day at 8:00 a.m. ET. According to Zimmer, the live audio webcast will be available under Zimmer's Investor Relations website and replay of the same will also be archived after the completion of the conference call. The Full Research Report on Zimmer Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9db9_ZMH]

ResMed Inc. Research Report

On October 2, 2013, ResMed Inc. (ResMed) announced the nomination of Carol J. Burt for an open position on the Company's board of directors. According to the Company, the election for the said nomination will be held at the annual meeting of stockholders in Sydney, Australia on November 14, 2013. ResMed informed that the board position for which Ms. Burt is nominated is currently held by Michael Quinn, who will not be standing for re-election. ResMed stated that currently Burt is a principal of Burt-Hilliard Investments, a private investment and consulting firm to the health care industry and prior to the current role, she served as Senior Vice President of Corporate Finance and Development for WellPoint, Inc. Ronald Taylor, Chairman of the ResMed Board's Nominating and Governance Committee, said, "Ms. Burt is highly regarded in the health care industry and has both practical and visionary experience to help guide ResMed's future, Under her leadership, she has helped companies rapidly scale to meet market opportunities. We look forward to having the privilege of her service on the ResMed board." The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/bd44_RMD]

Varian Medical Systems Inc. Research Report

October 7, 2013, Varian Medical Systems (Varian) announced that it will report its Q4 FY 2013 financial results on Wednesday, October 23, 2013 after the market closes. The Company informed that it will also host a teleconference on the same day at 2:00 p.m. PT. Varian stated that the news release and a link to the conference call webcast will be available on the Company's website. The Full Research Report on Varian Medical Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/bd48_VAR]

Opko Health, Inc. Research Report

On October 10, 2013, Opko Health Inc. (Opko) announced that it has agreed to make a strategic investment in Zebra Biologics, Inc., a privately held biotechnology company, which is focused on the discovery and development of biosuperior antibody therapeutics and complex drug targets. Phillip Frost, M.D., OPKO's Chairman and CEO, said, "This participation is in keeping with a core strategy of investing in other companies that have valuable proprietary technology and significant future potential for OPKO. We are hopeful that our portfolio of investments will continue to appreciate in value as the companies and technologies mature. In some cases, our investments offer opportunities for OPKO to obtain new products; as well as the possibility to monetize them at an appropriate time." The Full Research Report on Opko Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cd43_OPK]

EnteroMedics, Inc. Research Report

On September 24, 2013, EnteroMedics Inc. (EnteroMedics) announced that it has received a formal response from the Food and Drug Administration (FDA) in relation with its Premarket Approval Application (PMA) for approval of the Maestro Rechargeable System as a treatment for obesity. The Company informed that response includes follow-up questions with regard to the application, pertaining to device testing and clinical data, including training programs for users and a post approval study. Mark B. Knudson, Ph.D., EnteroMedics' President and CEO said, "We are very encouraged by the responsiveness of the FDA and are confident in our ability to address their questions in a timely manner, We will continue to work closely with the FDA throughout this process. We believe that the Company continues on track for a panel in late Q4 2013/Q1 2014 with approval decision in the first half of 2014." The Full Research Report on EnteroMedics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d32d_ETRM]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner